Investment Analysts’ Weekly Ratings Updates for Teleflex (TFX)

Teleflex (NYSE: TFX) recently received a number of ratings updates from brokerages and research firms:

• 3/2/2026 – Teleflex was downgraded by Zacks Research from “hold” to “strong sell”.
• 2/27/2026 – Teleflex had its price target raised by Royal Bank Of Canada from $115.00 to $125.00. They now have a “sector perform” rating on the stock.
• 2/27/2026 – Teleflex had its price target raised by Wells Fargo & Company from $116.00 to $130.00. They now have an “equal weight” rating on the stock.
• 2/26/2026 – Teleflex had its price target raised by Needham & Company LLC from $138.00 to $147.00. They now have a “buy” rating on the stock.
• 1/29/2026 – Teleflex had its price target lowered by Wells Fargo & Company from $139.00 to $116.00. They now have an “equal weight” rating on the stock.
• 1/27/2026 – Teleflex was upgraded by Needham & Company LLC from “hold” to “buy”. They now have a $138.00 price target on the stock.

Teleflex Dividend Announcement

The business also recently disclosed a quarterly dividend, which will be paid on Tuesday, March 31st. Stockholders of record on Friday, March 6th will be issued a $0.34 dividend. This represents a $1.36 annualized dividend and a dividend yield of 1.2%. The ex-dividend date of this dividend is Friday, March 6th. Teleflex’s payout ratio is -6.62%.

Teleflex Incorporated is a diversified global provider of medical technologies, specializing in critical care and surgery. Headquartered in Wayne, Pennsylvania, the company designs, manufactures and distributes devices and solutions used by healthcare professionals in hospital, ambulatory and alternate site settings. Teleflex focuses on delivering products that support complex interventional procedures and improve patient outcomes.

The company’s offerings span several key segments, including Interventional Urology, Respiratory & Anesthesia, Surgical, Cardiac Care, Vascular and Original Equipment Manufacturer (OEM) solutions.